SciTech’s initial target markets are T-cell lymphoma ($250M) and small cell lung cancer (>$700M) for a total initial addressable market of $950M+.  The initial T-cell lymphoma addressable market reflect targeted subsets of the disease state; notably, PTCL+CTCL+AITL+Sezáry Syndrome (global prevalence of 7,400). While the small cell lung cancer addressable market reflects a global prevalence of 10,000.

 

Fenretinide is cytotoxic in various cancer cell lines, including neuroblastoma, leukemia, and lymphoma (Mohrbacher et al., 2007)*. Given below are cancer indications in which clinical or pre-clinical evidence  supports the use of fenretinide as a therapeutic agent and represent SciTech’s future target markets (global values that could easily lead to a multi-billion-dollar addressable market).

​

 

 

 

 

 

 

 

 

 

 

 

National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Database and Statistics (https://seer.cancer.gov/)

 

SciTech’s focus is bringing to market a single-mode drug therapy; notably, its lead drug candidate ST-001 nanoFenretinide as a standalone treatment.

 

SciTech has entered into a collaborative agreement with Ferndale Laboratories Inc., which specializes in dermatological products, for a new topical drug application. SciTech and Ferndale are preparing IND filing of a topical formulation of ST-001 nanoFenretinide for skin cancer treatment, specifically: basal cell carcinoma, squamous cell carcinoma and actinic keratosis (AK, a precancerous condition) after having completed all preclinical studies.
 

Combination therapy opportunities may also avail themselves. These potential combination deals may be particularly attractive to SciTech as out-licensing or co-development opportunities for further revenue generation. Some possible combination deals include the following:  

​

​

​

​

​

 

 

​

 

Fenretinide's unique modes of action makes ST-001 nanoFenretinide particularly well-suited for combination therapy. Specifically, ST-001 nanoFenretinide is ideally suited for combination therapies with existing oncology drugs as well as with the immuno-oncology drugs that have recently entered the market. In fact, ST-001 nanoFenretinide may provide synergy in combinations with the checkpoint inhibitors class of immunotherapy and related cancer drugs.

 

Stand-alone drug and drug combination strategies represent several multibillion-dollar market opportunities for SciTech. Additionally, SciTech's nanoparticle drug delivery technology (SDP) holds the promise of enhancing the therapeutic performance of other cancer and non-cancer drugs with similar solubility profiles.

​

Value Proposition - Fenretinide has been uniquely validated by Phase I clinical trial data in the past. By reconfirming this efficacy and establishing the safety of ST-001 nanoFenretinide in a Phase I T-cell lymphoma trial, SciTech will be enabling this anticancer agent’s much anticipated potential.

​

*Ann Mohrbacher, Martin Gutierrez, Anthony J. Murgo, Shivaani Kummar, C. Patrick Reynolds, Barry J. Maurer, Susan Groshen, Lori Vergara, Min H. Kang, Allen S. Yang; Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.. Blood 2007; 110 (11): 2581. doi: https://doi.org/10.1182/blood.V110.11.2581.2581

​